ALGS Aligos Therapeutics Inc
Price (delayed)
$14.03
Market cap
$44.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$14.5
Enterprise value
$9.53M
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver
Highlights
Aligos Therapeutics's EPS has soared by 70% YoY and by 44% from the previous quarter
Aligos Therapeutics's net income has increased by 24% QoQ and by 8% YoY
ALGS's quick ratio is down by 33% since the previous quarter but it is up by 20% year-on-year
Aligos Therapeutics's equity has increased by 12% QoQ but it has decreased by 3.5% YoY
ALGS's revenue has dropped by 54% year-on-year and by 42% since the previous quarter
ALGS's gross profit has dropped by 54% year-on-year and by 42% since the previous quarter
Key stats
What are the main financial stats of ALGS
Market
Valuations
Earnings
Shares outstanding
3.2M
Market cap
$44.84M
Enterprise value
$9.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.65
Price to sales (P/S)
11.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
Revenue
$7.97M
EBIT
-$93.53M
EBITDA
-$90.79M
Free cash flow
-$85.34M
Per share
Balance sheet
Liquidity
EPS
-$14.5
Free cash flow per share
-$13.64
Book value per share
$21.52
Revenue per share
$1.27
TBVPS
$17.39
Total assets
$108.81M
Total liabilities
$41.58M
Debt
$9.84M
Equity
$67.23M
Working capital
$76.01M
Debt to equity
0.15
Current ratio
4.23
Quick ratio
4.01
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-1,139.6%
Gross margin
100%
Net margin
-950.6%
Operating margin
-1,173.9%
Return on assets
-63.9%
Return on equity
-110.6%
Return on invested capital
-245%
Return on capital employed
-109.7%
Return on sales
-1,173.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALGS stock price
How has the Aligos Therapeutics stock price performed over time
Intraday
1.67%
1 week
17.5%
1 month
3.54%
1 year
-29.85%
YTD
-15.48%
QTD
60.34%
Financial performance
How have Aligos Therapeutics's revenue and profit performed over time
Revenue
$7.97M
Gross profit
$7.97M
Operating income
-$93.53M
Net income
-$75.74M
Gross margin
100%
Net margin
-950.6%
The operating margin has dropped by 139% year-on-year and by 88% since the previous quarter
The company's net margin has shrunk by 99% YoY and by 32% QoQ
ALGS's revenue has dropped by 54% year-on-year and by 42% since the previous quarter
ALGS's gross profit has dropped by 54% year-on-year and by 42% since the previous quarter
Growth
What is Aligos Therapeutics's growth rate over time
Valuation
What is Aligos Therapeutics stock price valuation
P/E
N/A
P/B
0.65
P/S
11.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.2
Aligos Therapeutics's EPS has soared by 70% YoY and by 44% from the previous quarter
Aligos Therapeutics's equity has increased by 12% QoQ but it has decreased by 3.5% YoY
The stock's price to book (P/B) is 9% less than its last 4 quarters average of 0.7
The stock's price to sales (P/S) is 90% more than its last 4 quarters average of 5.7
ALGS's revenue has dropped by 54% year-on-year and by 42% since the previous quarter
Efficiency
How efficient is Aligos Therapeutics business performance
Aligos Therapeutics's ROS has plunged by 139% YoY and by 88% from the previous quarter
The return on equity has declined by 28% year-on-year but it rose by 23% since the previous quarter
The company's return on invested capital rose by 27% QoQ and by 4.7% YoY
ALGS's return on assets is up by 24% since the previous quarter but it is down by 4.6% year-on-year
Dividends
What is ALGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALGS.
Financial health
How did Aligos Therapeutics financials performed over time
The total assets is 162% more than the total liabilities
The total liabilities has declined by 39% since the previous quarter but it is up by 14% year-on-year
ALGS's quick ratio is down by 33% since the previous quarter but it is up by 20% year-on-year
The company's debt is 85% lower than its equity
The company's debt fell by 21% YoY and by 6% QoQ
ALGS's debt to equity is down by 17% QoQ and by 17% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.